Cerenis Therapeutics, Inc.
900 Victors Way
42 articles with Cerenis Therapeutics, Inc.
Cerenis Therapeutics announces its cash position for Q3 2018 and highlights the progress made over the period and key perspectives for the end of 2018
Progress in Q3 2018
CERENIS to Present New Data Validating HDL Targeted Drug Delivery in the Field of Oncology and Immuno-Oncology at the 30th EORTC/NCI/AACR1 Symposium
Cerenis Therapeutics (FR0012616852 – CEREN – PEA-PME eligible) (Paris:CEREN), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases,
Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.
Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director
Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the appointment of Barbara Yanni to its Board of Directors as an Independent Director.
Cerenis Announces Financing from Investment Funds, Management, Its Board of Directors and Its Oncology Scientific Advisory Board
Cerenis Therapeutics announces a capital increase of more than one million euros for the financing of its immuno-oncology activities.
CERENIS Therapeutics and University of North Texas Health Science Center Announce a Strategic Initiative to Develop New HDL-Based Pharmaceutical Products
This joint program is another marker of Cerenis' strategic evolution into a company with novel HDL platforms for drug delivery.
Seasoned Scientific Experts and Strategic Pharmaceutical Industry Veterans Join Cerenis’ Scientific Advisory Board in Oncology
CERENIS Therapeutics announces the creation of its Scientific Advisory Board in Oncology (SAB-Oncology) with five key appointments.
First Patients Enter TARGET Study, Recently Initiated by Cerenis Therapeutics to Evaluate HDL Nanoparticles in Patients with Esophageal Cancer
TARGET is the first ever performed clinical study testing the potential of labelled HDL to visualize tumors in cancer patients.
CERENIS Therapeutics Acquires LYPRO Biosciences Expanding Its HDL Strategy Into Immuno-Oncology and Chemotherapeutic Drug Delivery
Financial terms of the LYPRO Biosciences assets acquisition by CERENIS Therapeutics are not disclosed.
Cerenis Therapeutics, Inc. Receives FDA IND Approval To Begin Studies With CER-209 In NAFLD And NASH
Cerenis Therapeutics, Inc. Announces Last Patient Dosed In CARAT Phase II Study With CER-001 In Post-Acute Coronary Syndrome Patients
Cerenis Therapeutics, Inc. Release: Publication Of The Location Clinical Study Results In The Renowned Scientific Journal Of The European Atherosclerosis Society
Cerenis Therapeutics, Inc. Featured Prominently At The 25th Conference Of The Asian Pacific Association For The Study Of The Liver (APASL)
Catalent Biologics And Cerenis Therapeutics, Inc. Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology
Cerenis Therapeutics, Inc.: New Data For CER-001 Presented In Key Oral Session At American Heart Association Conference 2015
Cerenis Therapeutics, Inc. Announces The Appointment Of A New Chief Medical Officer And New Board Members
Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies